Acrivon Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Acrivon Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $8.00K.
- Acrivon Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $1.00K, a 98.73% decline year-over-year.
- Acrivon Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $11.00K, a 97.10% decline year-over-year.
- Acrivon Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $79.00K.
- Acrivon Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $1.00K, a 98.89% decline from fiscal 2024.
- Acrivon Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $90.00K, a 88.39% decline from fiscal 2023.
- Acrivon Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $775.00K, a 3129.17% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $24.00K, a 2300.00% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $8.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $1.00K 10-K · filed 2026-03-19 | |
| 2025-03-31 | $1.00K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $90.00K 10-K · filed 2026-03-19 | |
| 2024-06-30 | $11.00K 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $79.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $775.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $78.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $379.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $24.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $24.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $1.00K 10-K · filed 2023-03-28 | |
| 2021-09-30 | $1.00K 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |